Linda M. Rorick‐Kehn

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski et al. · Psychopharmacology · 2007 · 157 citations

Medicine, Pharmacology, Psychiatry +8

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 153 citations

Medicine, Medicinal Chemistry, Pharmacology +7

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

J M Witkin, James A. Monn, Darryle D. Schoepp et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 106 citations

Medicine, Neuroscience, Pharmacology +17

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models

Rachel I. Anderson, Howard C. Becker, Benjamin L. Adams et al. · Frontiers in Neuroscience · 2014 · 97 citations · Full text

Medicine, Neuroscience, Pharmacology +16

Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1 R,4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

Linda M. Rorick‐Kehn, Bryan G. Johnson, Jennifer Burkey et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 93 citations

Medicine, Pharmacokinetics, Pharmacology +14